Todd A. Huffman
Oprichter bij Padlock Therapeutics, Inc.
Profiel
Todd A.
Huffman is the founder of Padlock Therapeutics, Inc., which was founded in 2014.
He holds the title of Director at Padlock Therapeutics, Inc. Dr. Huffman is currently working as the Director-Clinical Translation Initiative at The University of Virginia School of Medicine.
Dr. Huffman previously worked as an Analyst at RCT BioVentures from 2007 to 2010.
Dr. Huffman obtained a doctorate degree from the University of Virginia in 2005.
Actieve functies van Todd A. Huffman
| Bedrijven | Functie | Begin |
|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Oprichter | 01-01-2014 |
| The University of Virginia School of Medicine | Corporate Officer/Principal | - |
Eerdere bekende functies van Todd A. Huffman
| Bedrijven | Functie | Einde |
|---|---|---|
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Private Equity Analist | 30-03-2010 |
Opleiding van Todd A. Huffman
| University of Virginia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Finance |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
